SCHEMBL439731

SCHEMBL439731

O=C(O)c1cccc2c1C(=O)NC2=O

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIG1 P18858 1/20 0.56
ALDH1A1 P00352 5/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MAPT P10636 2/20 0.55
LMNA P02545 1/20 0.55
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 2/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
HNF4A P41235 1/20 0.47
GSK3B P49841 1/20 0.46
POLB P06746 3/20 0.46
MYC P01106 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
CASP3 P42574 5/20 0.45
PARP1 P09874 1/20 0.44
ALOX15 P16050 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10349769 0.87 ALDH1A1 (0.54) LIG1ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL10339858 0.83 KEAP1 (0.56) LIG1ALDH1A1L3MBTL1KDM4EHSD17B10
SCHEMBL5128860 0.83 KDM4E (0.58) LIG1ALDH1A1L3MBTL1KDM4EHSD17B10
SCHEMBL9686151 0.82 CASP3 (0.51) LIG1ALDH1A1L3MBTL1MAPTLMNA
Phthalic Acid SCHEMBL28249734 0.82 GSK3B (0.65) LIG1ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL11612938 0.81 KDM4E (0.49) LIG1ALDH1A1L3MBTL1MAPTKDM4E
SCHEMBL10498838 0.81 POLB (0.46) LIG1ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL2823345 0.80 KDM4E (0.47) LIG1ALDH1A1L3MBTL1KDM4EHSD17B10
Phthalic Acid SCHEMBL28572075 0.80 GSK3B (0.62) LIG1ALDH1A1L3MBTL1MAPTLMNA
SCHEMBL10967338 0.79 KEAP1 (0.59) LIG1ALDH1A1L3MBTL1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140322646-A1 ABLATION IMAGEABLE LITHOGRAPHIC PRINTING PLATE NPEC INC. 2014-10-30 US claimed
US-20140065407-A1 MANUFACTURE OF LITHOGRAPHIC PRINTING PLATE PRECURSORS FOR ABLATION IMAGING KODAK REALTY INC. 2014-03-06 US claimed
WO-2012106169-A1 METHOD FOR PREPARING LITHOGRAPHIC PRINTING PLATES EASTMAN KODAK COMPANY (US) 2012-08-09 WO claimed
US-20120192741-A1 METHOD FOR PREPARING LITHOGRAPHIC PRINTING PLATES NPEC INC. 2012-08-02 US claimed
WO-2012099833-A1 PREPARING LITHOGRAPHIC PRINTING PLATES BY ABLATION IMAGING EASTMAN KODAK COMPANY (US) 2012-07-26 WO claimed
US-20120189770-A1 PREPARING LITHOGRAPHIC PRINTING PLATES BY ABLATION IMAGING KODAK REALTY INC. 2012-07-26 US claimed
US-7138425-B2 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2006-11-21 US claimed
US-20050203153-A1 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2005-09-15 US claimed
JP-6239017-A None JP disclosed
EP-3345055-B1 LITHOGRAPHIC DEVELOPER COMPOSITION AND METHOD OF USE EASTMAN KODAK CO (US) 2019-09-18 EP disclosed
CN-110028439-A Phthalimide analog derivative and its preparation method and application 四川大学 2019-07-19 CN disclosed
WO-2018177861-A1 SYMMETRICAL TRIS-ARYL-AMIDE DERIVATIVES AND THEIR USE AS ANTI-HEPARANASE LEADIANT BIOSCIENCES SA IN LIQUIDAZIONE (CH) 2018-10-04 WO disclosed
EP-3381898-A1 SYMMETRICAL TRIS-ARYL-AMIDE DERIVATIVES AND THEIR USE AS ANTI-HEPARANASE Leadiant Biosciences SA (CH) 2018-10-03 EP disclosed
EP-3345055-A1 LITHOGRAPHIC DEVELOPER COMPOSITION AND METHOD OF USE Eastman Kodak Company (US) 2018-07-11 EP disclosed
US-4306072-A ANXIOLYTIC AND PSYCHOSTIMULANT ACTIVITY FOR TREATMENT OF PSYCHOLOGICAL DISORDERS SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE (FR) 1981-12-15 US disclosed
US-4268512-A ANXIOLYTIC AGENTS, PSYCHOSTIMULANTS SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1981-05-19 US disclosed
US-4255580-A TREATMENT OF PSYCHOLOGICAL DISORDERS SIOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1981-03-10 US disclosed
US-4248885-A FOR GASTROINTESTINAL, UROGENITAL, RHEUMATIC, AND CARDIOVASCULAR DISEASE SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1981-02-03 US disclosed
US-4229443-A Derivatives of penicillanic acid LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) 1980-10-21 US disclosed
US-4186135-A TREATMENT OF PSYCHOLOGICAL DISORDERS SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1980-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203153-A1 Phthalimide carboxylic acid derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 LIG1 2558/4885ALDH1A1 160/4885L3MBTL1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.